GSA Capital Partners LLP raised its holdings in Chemed Co. (NYSE:CHE) by 75.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,765 shares of the company’s stock after buying an additional 2,487 shares during the period. GSA Capital Partners LLP’s holdings in Chemed were worth $1,165,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in Chemed by 1.9% in the second quarter. Vanguard Group Inc. now owns 1,830,711 shares of the company’s stock valued at $374,435,000 after buying an additional 34,938 shares during the period. State Street Corp raised its stake in Chemed by 1.8% in the second quarter. State Street Corp now owns 453,605 shares of the company’s stock valued at $92,782,000 after buying an additional 8,238 shares during the period. Investec Asset Management LTD raised its stake in Chemed by 1.8% in the third quarter. Investec Asset Management LTD now owns 323,231 shares of the company’s stock valued at $65,309,000 after buying an additional 5,717 shares during the period. Voya Investment Management LLC increased its stake in shares of Chemed by 39.7% during the second quarter. Voya Investment Management LLC now owns 214,764 shares of the company’s stock worth $43,926,000 after purchasing an additional 61,056 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in shares of Chemed by 111.5% during the third quarter. JPMorgan Chase & Co. now owns 182,551 shares of the company’s stock worth $36,125,000 after purchasing an additional 96,237 shares during the period. Hedge funds and other institutional investors own 97.71% of the company’s stock.

CHE has been the topic of a number of recent research reports. Oppenheimer increased their target price on Chemed from $220.00 to $225.00 and gave the stock an “outperform” rating in a research note on Friday, October 27th. Zacks Investment Research lowered Chemed from a “buy” rating to a “hold” rating in a research note on Wednesday, September 13th. Royal Bank of Canada increased their target price on Chemed to $232.00 and gave the stock a “sector perform” rating in a research note on Tuesday, October 31st. KeyCorp reiterated a “hold” rating on shares of Chemed in a research note on Friday, October 27th. Finally, ValuEngine lowered Chemed from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $236.00.

In related news, insider David Patrick Williams sold 11,000 shares of the stock in a transaction that occurred on Wednesday, November 29th. The stock was sold at an average price of $241.28, for a total transaction of $2,654,080.00. Following the sale, the insider now owns 74,857 shares of the company’s stock, valued at $18,061,496.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Michael D. Witzeman sold 1,000 shares of the stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $250.00, for a total value of $250,000.00. Following the sale, the vice president now directly owns 3,334 shares in the company, valued at approximately $833,500. The disclosure for this sale can be found here. Insiders have sold 46,179 shares of company stock worth $10,729,699 in the last three months. 4.90% of the stock is currently owned by company insiders.

Chemed Co. (NYSE:CHE) opened at $242.41 on Friday. The firm has a market capitalization of $3,853.87, a P/E ratio of 29.73, a PEG ratio of 5.10 and a beta of 1.16. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.48 and a current ratio of 0.50. Chemed Co. has a 52 week low of $155.82 and a 52 week high of $251.00.

Chemed (NYSE:CHE) last announced its earnings results on Thursday, October 26th. The company reported $2.15 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.00 by $0.15. The company had revenue of $417.40 million for the quarter, compared to analyst estimates of $414.34 million. Chemed had a return on equity of 27.69% and a net margin of 4.62%. The firm’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter last year, the company earned $1.73 earnings per share. research analysts expect that Chemed Co. will post 4.73 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Monday, December 4th. Investors of record on Monday, November 13th were given a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 0.46%. The ex-dividend date was Friday, November 10th. Chemed’s dividend payout ratio is currently 24.89%.

TRADEMARK VIOLATION WARNING: “Chemed Co. (CHE) Shares Bought by GSA Capital Partners LLP” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/12/23/chemed-co-che-shares-bought-by-gsa-capital-partners-llp.html.

Chemed Profile

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE).

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Stock Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related stocks with our FREE daily email newsletter.